Unfortunately, abnormal activation of the PI3K/AKT/mTOR signaling pathway could promote cancer cells resistant to anti-HER2 therapies and the side effects (e.g., bone marrow suppression and cardiomyopathy) severely restrict the therapeutic efficacy14–16. This evidence concerns the gene ERBB2 and cancer.